connbio | Abstract Finder

Abstract Number: 893 – Venetoclax Plus Dexamethasone As First-Line Treatment for t(11; 14) Light-Chain Amyloidosis: Preliminary Result of a Phase II Prospective, Multicenter, Single-Arm Study

Presenter: Kaini Shen, MDSession: 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Ignored no Longer-Progress in AL AmyloidosisDate & Time: Monday, December 9, 2024 3:45 PM–4:00 PMLocation: Pacific Ballroom...

Abstract Number: 892 – Efficacy and Safety of Isatuximab, Pomalidomide and Dexamethasone in Relapsed AL Amyloidosis: Interim Results of the Isamyp Phase 2 Joint Study from the IFM and ALLG

Presenter: Murielle Roussel, MDSession: 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Ignored no Longer-Progress in AL AmyloidosisDate & Time: Monday, December 9, 2024 3:30 PM–3:45 PMLocation: Pacific Ballroom...

Abstract Number: 891 – Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study

Presenter: Efstathios Kastritis, MDSession: 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Ignored no Longer-Progress in AL AmyloidosisDate & Time: Monday, December 9, 2024 3:15 PM–3:30 PMLocation: Pacific...

Abstract Number: 889 – Clinical Significance of Measurable Residual Disease (MRD) in Light-Chain (AL) Amyloidosis

Presenter: Bruno Paiva, PhDSession: 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Ignored no Longer-Progress in AL AmyloidosisDate & Time: Monday, December 9, 2024 2:45 PM–3:00 PMLocation: Pacific Ballroom...

Abstract Number: 773 – Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study

Presenter: Meletios-Athanasios DimopoulosSession: 654. Multiple Myeloma: Pharmacologic Therapies: Refining the Evidence: Randomized Trials in Multiple MyelomaDate & Time: Monday, December 9, 2024 11:30 AM–11:45 AMLocation: Pacific Ballroom Salons 21-22 (Marriott...

« Older Entries

Next Entries »

Abstract Number: 893 – Venetoclax Plus Dexamethasone As First-Line Treatment for t(11; 14) Light-Chain Amyloidosis: Preliminary Result of a Phase II Prospective, Multicenter, Single-Arm Study

Abstract Number: 892 – Efficacy and Safety of Isatuximab, Pomalidomide and Dexamethasone in Relapsed AL Amyloidosis: Interim Results of the Isamyp Phase 2 Joint Study from the IFM and ALLG

Abstract Number: 891 – Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study

Abstract Number: 889 – Clinical Significance of Measurable Residual Disease (MRD) in Light-Chain (AL) Amyloidosis

Abstract Number: 773 – Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study

Recent Posts

Recent Comments

Archives

Categories

Meta